CURRICULUM VITAE East Riverside Boulevard Rockford, IL 61114

Transcription

1 CURRICULUM VITAE Name: Present Employer: David J. Dansdill, M.D., F.A.C.R. OrthoIllinois 5875 East Riverside Boulevard Rockford, IL Date Affiliated: January 2003 Date of Birth: July 25, 1958 Place of Birth: Burlington, Iowa Education: Premedical: Medical: Residency: Fellowship: University of Kansas, Lawrence, Kansas Degree B.A., Biology, 1980 University of Kansas, Kansas City, Kansas Degree M.D., 1985 Internal Medicine, University of Kansas School of Medicine, Wichita, Kansas, Chief Resident: Internal Medicine, University of Kansas School Of Medicine, Wichita, Kansas, University of Missouri, Columbia, Immunology & Rheumatology, Board Certification: National Board of Medical Examiners Diplomate, 1988 American Board of Internal Medicine, Certified, 1989 American Board of Internal Medicine, Rheumatology, 1992, 2002, 2012 State Licensure: Kansas, 1986 Missouri, 1989 Illinois, 1991 ( ) Hospital Affiliation: Organizations: Appointments: Rockford Memorial Hospital OSF Saint Anthony Medical Center SwedishAmerican Hospital Van Matre HealthSouth Rehabilitation Hospital American College of Physicians American Medical Association Boone County Medical Association Kansas Medical Society Captain, U.S. Army Reserve 971 st Medical Clearing Company, Rheumatology Fellow University of Missouri Columbia, Missouri Clinical Assistant Professor University of Illinois College of Medicine Department Chairman Non-Invasive Medicine Subspecialties RHS

2 David J. Dansdill, M.D. Page 2 of 7 Abstracts: Dansdill, D.J. and Young, D.: Hereditary Angioedema. Presented at the American College of Physicians, Kansas Chapter Meeting, Wichita, Kansas, September 1987 Dansdill, D.J. and Jawadi, M.H.: Factor VII Deficiency. A case presentation and review of syndrome. Presented at the American College of Physicians, Kansas Chapter Meeting, Kansas City, Missouri, October 8-9, Dow, S.B., Olson, D., Dansdill, D.J., and Nowlin, N.: Quantitation of Rheumatoid Arthritis. Presented at the American College of Physicians, Kansas Chapter Meeting, Wichita, Kansas, September 9-10, Publications: Research Projects: A1/Learn Rheumatology. A Computer-Assisted Educational System for Teaching about Rheumatic Diseases, Arthritis Care & Research, Vol. 5, No 1, March ) Pfizer, Inc., Co-Investigator. Multicenter Double-Blind Study of Two Dose Ranges of Tenidap Sodium Versus Piroxicam in Patients with Osteoarthritis of the Knee or Hip. 2) Pfizer, Inc., Co-Investigator. Multicenter Double-Blind Study of Tenidap Sodium Alone, Naproxen Alone, and Naproxen with Auranofin. 3) Fidia, Co-Investigator. The Efficacy and Safety of Intra-articular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo- and Naproxen- Controlled, Multicenter Clinical Trial. 4) Upjohn, Co-Investigator. A Comparison of ANSAID Tablets and Etodolac in the Treatment of Osteoarthritis of the Knee. 5) Wyeth-Ayerst, Co-Investigator. Placebo-Controlled Comparison of the Efficacy and Safety of Two Dosing Intervals of Orally Administered Etodolac to Naproxen in Patients with Osteoarthritis of the Knee. 6) Pfizer, Inc., Co-Investigator. Multicenter, Double-Blind, Placebo-Controlled Study of Piroxicam in Patients with Osteoarthritis of the Knee. 7) Pfizer, Inc. Multicenter, Double-Blind, Placebo-Controlled, Fixed Dose, Dose-Response Study of CP-72, 133 in Patients with Rheumatoid Arthritis, ) Pfizer, Inc. Multicenter, Double-Blind, Placebo-Controlled, Fixed Dose, Dose-Response Study of CP-72, 133 in Patients with Osteoarthritis,

3 David J. Dansdill, M.D. Page 3 of 7 9) Ostex International, Inc., Co-Investigator. A Study of the Use of Osteomark in the Assessment of Changes in Bone Resorption Rates Resulting from Estrogen Deficiency. 10) Sanofi-Winthrop, Co-Investigator. A Randomized, Double-Blind Trial Comparing the Onset of Action of Three Loading Doses of Hydroxychloroquine (Plaquenil) (PLA-SW-008 and PLA-SW- 009) and the Steroid-Sparing Effect of Hydroxychloroquine After Maintenance Treatment in Rheumatoid Arthritis Patients (PLA- SW-010). 11) Wyeth-Ayerst, Co-Investigator. Comparison of the Safety and Efficacy of Three Loading Doses of Bromfenac, Naproxen, and Placebo in Patients with Active Osteoarthritis of the Knee with an Open-Label Extension. Protocol 792-A-314-US. 12) G.D. Searle, Co-Investigator. Double-Blind, Placebo-Controlled Comparative Study of the Efficacy and Upper Gastrointestinal Safety of Diclofenac 75 mg BID, Diclo-fenac 50 mg/misoprostol, 200 mcg TID and Diclofenac 75 mg/misoprostol 200 mcg BID in Treating the Signs and Symptoms of Osteoarthritis. Document No. NN ) Ciba-Geigy, Co-Investigator. A Comparison of Diclofenac Potassium, Naprosyn (Naproxen) and Placebo in the Treatment of Acute Sprains and Strains of the Ankle. Protocol ) The Purdue Frederick Company, Co-Investigator. A Six-Month, Open-Label, Analgesic Efficacy, Safety Acceptability and Quality of Life Study of Controlled-Release Oxycodone Tablets in Chronic Non-Malignant Pain Due to Osteoarthritis with an Optional Six-Month Extension. OC ) GenDerm, Principal Investigator. A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Topical Capsaicin Cream in Subjects with Osteoarthritis of the Knee. Protocol No ) GenDerm, Principal Investigator. An Open-Label Chronic Dosing, Multicenter Study Evaluating the Long-Term Safety of Capsaicin Cream in Subjects with Osteoarthritis. Protocol No ) RAIN, Co-Investigator. The Safety and Efficacy of Treatment of Early Rheumatoid Arthritis with Minocycline.

4 David J. Dansdill, M.D. Page 4 of 7 18) Boots Pharmaceuticals, Co-Investigator. A Study of the Efficacy and Safety of Flurbiprofen Local Action Trans-cutaneous (LAT) in the Treatment of Lateral Epicondylitis. BPI ) Wyeth-Ayerst, Co-Investigator. A Double-Blind, Crossover Comparison of the Efficacy and Safety of Etodolac Extended Release with Etodolac in Patients with Osteoarthritis of the Knee. 20) Ortho-McNeil Pharmaceutical, Co-Investigator. An Evaluation of the Analgesic Efficacy and Safety of Ultram Compared to Ibuprofen in Subjects with Chronic Pain of Osteoarthritis. 21) The Purdue Frederick Company, Co-Investigator. Open-Label, Clinical Use Study of Controlled-Release Oxycodone Tablets Administered Orally Every 12 Hours for the Management of Pain. Protocol No. OC ) Merck & Co., Inc., Co-Investigator. An Open-Label Study to Evaluate the Safety and Pattern of Use of Flexeril MR in Patients with Painful Muscle Spasm. 23) Wyeth-Ayerst, Co-Investigator. Placebo-Controlled Comparison of the Safety and Efficacy of Two Doses of Etodolac Extended Release with Nabumetone in Patients with Osteoarthritis of the Knee. Protocol No. 654-D-371-US. 24) Hoechst SBU Rheumatology, Co-Investigator. Phase III, Double- Blind, Randomized, Placebo-Controlled Study to Compare the Activity and Safety of Leflunomide to Methotrexate or Placebo in Subjects with Active Rheumatoid Arthritis. 25) Wyeth-Ayerst, Co-Investigator. A Double-Blind Comparison of Bromfenac Versus Acetaminophen/Hydrocodone in Patients with Acute Soft Tissue Injury. Protocol No. 792-A-332-US. 26) G.D. Searle & Co., Co-Investigator. Clinical Protocol for a Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Oxaprozin Potassium 1200 mg Q.D., Oxaprozin Acid 1200 mg Q.D., and Placebo in the Treatment of Osteoarthritis of the Knee with 18- Week Follow-Up. Protocol No. N ) Pfizer, Inc., Co-Investigator. A Randomized, Double-Blind Study Evaluating the Efficacy and Safety of the Combination of Tenidap with Methotrexate in Patients with Rheumatoid Arthritis. Protocol No. L ) Merck & Co., Co-Investigator. A 6-Month, Double-Blind, Placebo-Controlled, Parallel Group Study of Oral MK-0677 in Hip Fracture Patients. Protocol No

5 David J. Dansdill, M.D. Page 5 of 7 29) SmithKline Beecham Pharmaceuticals, Co-Investigator. Phase 1 Repeat Dose, Dose Rising Safety and Pharmacokinetic Trial of SKF (Atiprimod) in Patients with Rheumatoid Arthritis. Protocol No ) G.D. Searle & Co., Co-Investigator. Clinical Protocol for Pilot Dose-Ranging Study to Evaluate the Safety and Efficacy of SC mg, 100 mg and 200 mg BID Versus Placebo in Treating the Signs and Symptoms of Osteoarthritis. Protocol No. N ) G.D. Searle & Co., C0-Investigator. Clinical Protocol for Pilot Dose-Ranging Study to Evaluate the Safety and Efficacy of SC mg, 200 mg and 400 mg BID Versus Placebo in Treating Signs and Symptoms of Rheumatoid Arthritis. Protocol No. N ) BBI/AutoImmune, Inc., Co-Investigator. A Phase II Double- Blind, Randomized, Placebo-Controlled, Four Group, Parallel, Dose Refinement Study of Oral Colloral in Adult Patients with Active Rheumatoid Arthritis. Protocol No. A ) Wyeth-Ayerst, Co-Investigator. A Double-Blind, Crossover, Comparison of the Efficacy and Safety of 1000 mg Etodolac Extended Release (Etodolac ER) with 1000 mg Etodolac Followed by an Open-Label Section with Etodolac Extended Release for Up to One Year in Patients with Osteoarthritis of the Knee. Protocol No. 654-D-374-US. 34) Wyeth-Ayerst, Co-Investigator. Comparison of the Efficacy and Safety of Etodolac Extended Release with Etodolac in Patients with Active Rheumatoid Arthritis Followed by a Long-Term Safety Evaluation. Protocol No. 654-D-376-US. 35) BRI/ Hoecst Roussel Pharmaceutical, Co-Investigator, A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Compare the Activity and Safety of Leflumomide to Methotrexate or Placebo in Subjects with Active Rheumatoid Arthritis Extension Protocol for: HWA 4861F1USA1301RA Protocol. No.: HSA1. 36) MTRA/Autoimmune, Co-Investigator, An Open-Label, Long- Term Safety Study of Chronically Administered Oral Colloral (Chicken Type II collagen-bb IND 6412) in Adult Patients with Rheumatoid Arthritis Who Have Participated in Colloral Study A , A or A Protocol No. A

6 David J. Dansdill, M.D. Page 6 of 7 37) Scirex/Searle, Co-Investigator, Clinical Protocol for a Multicenter, Double-Blind, Placebo-Controlled Parallel Group Comparison Study of the Safety and Efficacy of Oxaprozin Potassium 1200 MG QD, Lodine (Etodolac) 400 MG BID and Placebo in the Treatment of Osteoarthritis of the Knee. Protocol No. N ) Parke-Davis, Co-Investigator, A Randomized, 6-Week Double- Blind, Placebo-and Postitive-Controlled, Parallel-Group, Multicenter, Dose-Ranging Study of C in Patients with Rheumatoid Arthritis. Protocol No ) Parke-Davis, Co-Investigator, A 6-Week Open-Label, Multicenter Safety Study of 10 MG C Capsules in Patients with Rheumatoid Arthritis. Protocol No ) B.R.I. Fujisawa, Co-Investigator, A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Efficacy and Safety of FK506 in the Treatment of Methotrexate Failed Rheumatoid RA-001 Arthritis Patients. Protocol No. FK ) Merck & Co., Inc., Co-Investigator, A Placebo and Active comparator-controlled, Parallel-Group, 6-Week, Double-Blind Study, Conducted Under In-House Blinding Conditions, to Assess the Safety and Efficacy of MK-0966 Versus Ibuprofen in Patients with Osteoarthritis of the Knee or Hip. Protocol No. MK ) Hyal Pharmaceutical Co., Co-Investigator, A Multicenter Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of Topical 3% Diclofenac Gel (Hyanalgese-D) in the Treatment of Pain Associated with Osteoarthritis of the Knee. Protocol No. AT ) Merck & Co., Inc., Co-Investigator, An Active Comparator and Placebo-Controlled, Parallel-Group, 6-Week, Double-Blind Study, Conducted Under In-House Blinding, to Assess Efficacy, Safety and Tolerability of MK-0966 in Patients Aged 80 and Over with Osteoarthritis of the Knee or Hip. Protocol No. MK ) Merck & Co., Inc., Co-Investigator, Double-Blind, Active Comparator-Controlled Extension to an Active Comparator and Placebo-Controlled, Double-Blind Study to Assess Efficacy, Safety, and tolerability of MK-0966 in Patients Aged 80 and Over with Osteoarthritis of the Knee or Hip. Protocol No. MK ) Tap Holdings Inc., Co-Investigator, Multicenter Dose-Response Study of Oral TAK-603/A in Rheumatoid Arthritis Patients. Protocol No. M

7 David J. Dansdill, M.D. Page 7 of 7 46) Tap Holdings Inc., Co-Investigator, An Open-Label, Long-Term Study of the Safety and Tolerability of Oral TAK-603 in Rheumatoid Arthritis Patients. Protocol NO. M ) Boehringer Ingelheim Pharmaceuticals, Inc., Co-Investigator, A Multicenter, Double-Blind, Double-Dummy, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (3.75, 7.5 and 15 mg) with Diclofenac (100 mg) and Placebo in Patients with Osteoarthritis. Protocol NO ) Boehringer Ingelheim Pharmaceuticals, Inc., Co-Investigator, A Multicenter, Double-Blind, Double-Dummy, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) with Placebo in Patients with Rheumatoid Arthritis; and with Diclofenac (150 mg) as an Active control to Assess Trial Sensitivity. Protocol No ) F. Hoffman-La Roche, Ltd., Co-Investigator, A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Multicenter Comparison of the Efficacy and Safety of Mycophenolate Mofetil (MMF RS 61442) po (1 g BID) and Neoral (Oral Cyclosporin Microemulsion Solution) in Patients with Active Rheumatoid Arthritis (6-Month Efficacy Study) Who are Candidates for Immunosuppressive Therapy of RA. Protocol No. BA 15430D. 50) F. Hoffman-La Roche, Ltd., Co-Investigator, An Open-Label, Multicenter, Study Administering Mycophenolate Mofetil (MMF RS 61443) po (1 g BID) in Patients with Active Rheumatoid Arthritis (Extension of Protocol BA 15430). Protocol No. BA 15431B 51) Merck & Co., Inc., Co-Investigator, A Randomized, Placebo and Active Comparator-Controlled, Parallel Group, Double-Blind Study to Compare the Efficacy and Safety of MK-0966 Tablets vs. Nabumetone Tablets in Patients with Osteoarthritis of the Knee. Protocol NO. COX ) G. D. Searle & Co., Co-Investigator, A Multicenter, Double- Blind, Parallel Group Study Comparing the Incidence of Clinically Significant Upper Gastrointestinal Adverse Events Associated with SC mg BID to that of NSAID Treatment with Either Diclofenac 75 mg BID, Ibuprofen 800 mg TID or Naproxen 500 mg BID in Patients with Osteoarthritis or Rheumatoid Arthritis. Protocol No. N /2011